FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969224144> ?p ?o ?g. }

• W1969224144 endingPage "56" @default.
• W1969224144 startingPage "1" @default.
• W1969224144 abstract "Background Peanut allergy is a common disease that causes severe and fatal food allergic reactions. Currently, the best treatment is avoidance as repeated reactions can occur. Quality of life (QoL) is reduced by fear of severe reactions and social limitations. Oral immunotherapy (OIT) is a novel treatment that may be an effective treatment for peanut allergy. Objectives To determine the efficacy of peanut OIT in children. Design A phase 2 randomised, controlled, crossover trial (open label). Setting Single UK centre study. Participants Children aged 7–15 years with peanut allergy diagnosed by double-blind, placebo-controlled food challenge (DBPCFC). No children were excluded because of anaphylaxis or asthma. Interventions Daily immunotherapy (2 mg, 5 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg and 800 mg of peanut protein) was administered as peanut flour (containing 50% peanut protein). Doses were increased at 2-weekly intervals to a maintenance dose of 800 mg of protein. The control group underwent peanut avoidance for 6 months during phase 1. Main outcome measure A peanut DBPCFC up to 1400 mg of peanut protein was performed in both groups at 6 months. The highest amount of peanut tolerated was the main outcome measure. Randomisation Randomised by online audited system to active or control group (1 : 1). Blinding The intervention arm allocation was not blinded. Methods We assigned 99 participants aged 7–16 years with peanut allergy of all severities to active OIT or control (peanut avoidance/current standard of care). The primary outcome was desensitisation, defined as negative peanut challenge (1400 mg of protein DBPCFC) at 6 months (phase 1). Control participants underwent OIT during phase 2, followed by DBPCFC. Immunological parameters and disease-specific QoL scores were measured. Results The primary outcome, desensitisation, was observed in 62% (24/39) of the active group and none (0/46) of the control group after phase 1 [95% confidence interval (CI) 45% to 78% vs. 0% to 9%; p < 0.001]; 84% (95% CI 70% to 93%) of the active group tolerated daily ingestion of 800 mg of protein (≈ five peanuts). Median increase in peanut threshold after OIT was 1345 mg (range 45–1400 mg; p < 0.001) or 2.5-fold (range 1.82–280-fold; p < 0.001). After phase 2, 54% (95% CI 35% to 72%) tolerated a 1400-mg challenge (≈ 10 peanuts) and 91% (95% CI 79% to 98%) tolerated a daily ingestion of 800 mg of protein. QoL scores improved (decreased) after OIT (median change –1.61; p < 0.001). Side effects were mostly mild with gastrointestinal symptoms being the most common: oral pruritus occurred after 6.3% of doses, wheeze occurred after 0.41% of doses (one-fifth of participants) and intramuscular epinephrine was required after 0.01% of doses (one participant). Conclusion In children with peanut allergy of any severity, OIT successfully induced desensitisation in the majority, with a clinically meaningful increase in peanut threshold. QoL improved after intervention and there was a good safety profile. Immunological changes reflected clinical desensitisation. Peanut OIT should not be undertaken in non-specialist settings. Future work will include a phase 3 confirmatory study and studies of long-term tolerance; similar studies of other allergens are also required. Trial registration Current Controlled Trials ISRCTN62416244. Funding This project was awarded by the Efficacy and Mechanism Evaluation programme and is funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC–NIHR partnership, and jointly sponsored by the University of Cambridge and Addenbrooke’s Hospital [Cambridge University Hospital Foundation Trust (RD authorisation A091686)]. The project will be published in full in Efficacy and Mechanism Evaluation ; Vol. 1, No. 4. See the NIHR Journals Library website for further project information." @default.
• W1969224144 created "2016-06-24" @default.
• W1969224144 creator A5005241960 @default.
• W1969224144 creator A5010334043 @default.
• W1969224144 creator A5018741279 @default.
• W1969224144 creator A5018814169 @default.
• W1969224144 creator A5034582010 @default.
• W1969224144 creator A5051267341 @default.
• W1969224144 creator A5059565310 @default.
• W1969224144 creator A5084298635 @default.
• W1969224144 creator A5091157379 @default.
• W1969224144 date "2014-12-01" @default.
• W1969224144 modified "2023-10-07" @default.
• W1969224144 title "Study of induction of Tolerance to Oral Peanut: a randomised controlled trial of desensitisation using peanut oral immunotherapy in children (STOP II)" @default.
• W1969224144 cites W1525297992 @default.
• W1969224144 cites W1531304022 @default.
• W1969224144 cites W1582454035 @default.
• W1969224144 cites W1741971985 @default.
• W1969224144 cites W1957257550 @default.
• W1969224144 cites W1976771675 @default.
• W1969224144 cites W1989102837 @default.
• W1969224144 cites W1989665816 @default.
• W1969224144 cites W1994247406 @default.
• W1969224144 cites W2000826674 @default.
• W1969224144 cites W2006208839 @default.
• W1969224144 cites W2006428370 @default.
• W1969224144 cites W2017778900 @default.
• W1969224144 cites W2024547469 @default.
• W1969224144 cites W2029661050 @default.
• W1969224144 cites W2036975801 @default.
• W1969224144 cites W2042106885 @default.
• W1969224144 cites W2050928602 @default.
• W1969224144 cites W2054171853 @default.
• W1969224144 cites W2059372582 @default.
• W1969224144 cites W2118532682 @default.
• W1969224144 cites W2125703217 @default.
• W1969224144 cites W2132083799 @default.
• W1969224144 cites W2312829609 @default.
• W1969224144 doi "https://doi.org/10.3310/eme01040" @default.
• W1969224144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25642539" @default.
• W1969224144 hasPublicationYear "2014" @default.
• W1969224144 type Work @default.
• W1969224144 sameAs 1969224144 @default.
• W1969224144 citedByCount "4" @default.
• W1969224144 countsByYear W19692241442016 @default.
• W1969224144 countsByYear W19692241442017 @default.
• W1969224144 countsByYear W19692241442018 @default.
• W1969224144 countsByYear W19692241442020 @default.
• W1969224144 crossrefType "journal-article" @default.
• W1969224144 hasAuthorship W1969224144A5005241960 @default.
• W1969224144 hasAuthorship W1969224144A5010334043 @default.
• W1969224144 hasAuthorship W1969224144A5018741279 @default.
• W1969224144 hasAuthorship W1969224144A5018814169 @default.
• W1969224144 hasAuthorship W1969224144A5034582010 @default.
• W1969224144 hasAuthorship W1969224144A5051267341 @default.
• W1969224144 hasAuthorship W1969224144A5059565310 @default.
• W1969224144 hasAuthorship W1969224144A5084298635 @default.
• W1969224144 hasAuthorship W1969224144A5091157379 @default.
• W1969224144 hasBestOaLocation W19692241441 @default.
• W1969224144 hasConcept C126322002 @default.
• W1969224144 hasConcept C142724271 @default.
• W1969224144 hasConcept C168563851 @default.
• W1969224144 hasConcept C187212893 @default.
• W1969224144 hasConcept C203014093 @default.
• W1969224144 hasConcept C204787440 @default.
• W1969224144 hasConcept C207480886 @default.
• W1969224144 hasConcept C27081682 @default.
• W1969224144 hasConcept C2771230 @default.
• W1969224144 hasConcept C2776027960 @default.
• W1969224144 hasConcept C2776042228 @default.
• W1969224144 hasConcept C2778012357 @default.
• W1969224144 hasConcept C71924100 @default.
• W1969224144 hasConceptScore W1969224144C126322002 @default.
• W1969224144 hasConceptScore W1969224144C142724271 @default.
• W1969224144 hasConceptScore W1969224144C168563851 @default.
• W1969224144 hasConceptScore W1969224144C187212893 @default.
• W1969224144 hasConceptScore W1969224144C203014093 @default.
• W1969224144 hasConceptScore W1969224144C204787440 @default.
• W1969224144 hasConceptScore W1969224144C207480886 @default.
• W1969224144 hasConceptScore W1969224144C27081682 @default.
• W1969224144 hasConceptScore W1969224144C2771230 @default.
• W1969224144 hasConceptScore W1969224144C2776027960 @default.
• W1969224144 hasConceptScore W1969224144C2776042228 @default.
• W1969224144 hasConceptScore W1969224144C2778012357 @default.
• W1969224144 hasConceptScore W1969224144C71924100 @default.
• W1969224144 hasFunder F4320319994 @default.
• W1969224144 hasFunder F4320334626 @default.
• W1969224144 hasIssue "4" @default.
• W1969224144 hasLocation W19692241441 @default.
• W1969224144 hasOpenAccess W1969224144 @default.
• W1969224144 hasPrimaryLocation W19692241441 @default.
• W1969224144 hasRelatedWork W1521380121 @default.
• W1969224144 hasRelatedWork W1965738072 @default.
• W1969224144 hasRelatedWork W2172283060 @default.
• W1969224144 hasRelatedWork W2435185574 @default.
• W1969224144 hasRelatedWork W2944267733 @default.
• W1969224144 hasRelatedWork W3030015530 @default.
• W1969224144 hasRelatedWork W3082594650 @default.

• next